Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 19/20 | 0.57 |
| ▸ | ITGA4 | P13612 | 19/20 | 0.57 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.56 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101344 | 1.00 | ITGB1 (0.57) | ITGB1ITGA4ITGA2ITGB7KMT2A | |
| SCHEMBL4516205 | 1.00 | ITGB1 (0.57) | ITGB1ITGA4ITGA2ITGB7KMT2A | |
| Hydrochloric Acid SCHEMBL5260907 | 0.99 | ITGB1 (0.56) | ITGB1ITGA4ITGA2ITGB7 | |
| Hydrochloric Acid SCHEMBL5259160 | 0.99 | ITGB1 (0.56) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL6639808 | 0.93 | ITGB1 (0.63) | ITGB1ITGA4ITGA2ITGB7 | |
| Hydrochloric Acid SCHEMBL6639802 | 0.92 | ITGB1 (0.62) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL18594974 | 0.92 | ITGB1 (0.57) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL27682875 | 0.91 | ITGB1 (0.49) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL27682876 | 0.91 | ITGB1 (0.49) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL4514318 | 0.88 | ITGB1 (0.61) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2806898-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN LA ROCHE (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
| EP-2806897-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING LFA-1 | HOFFMANN LA ROCHE (CH) | 2017-08-02 | — | — | EP | disclosed |
| EP-2806899-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-20150031715-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN-LA ROCHE INC. | 2015-01-29 | — | — | US | disclosed |
| WO-2013110679-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING LFA-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013110578-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013110681-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013110680-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| US-7618983-B2 | Bicyclic triazole α4 integrin inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-11-17 | — | — | US | disclosed |
| CN-100536839-C | Urea derivatives as integrin alpha 4 antagonists | ALMIRALL PRODESFARMA SA (ES) | 2009-09-09 | — | — | CN | disclosed |
| CN-100369888-C | N-alkanoylphenylalanine derivatives | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | CN | disclosed |
| WO-2006090234-A1 | HETEROCYCLIC DERIVATIVES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | WO | disclosed |
| US-20060128748-A1 | Bicyclic triazole alpha4 integrin inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-06-15 | — | — | US | disclosed |
| WO-2006052962-A2 | BICYCLIC TRIAZOLE A4 INTEGRIN INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-18 | — | — | WO | disclosed |
| CN-1531425-A | Urea derivatives as integrin alpha 4 antagonists | ������ҩ������˾ | 2004-09-22 | — | — | CN | disclosed |
| CN-1281430-A | N-alkanoylphenylalanine derivatives | HOFFMANN LA ROCHE (CH) | 2001-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGB4 | ITGB1 1/4885ITGA4 2/4885ITGA2 9/4885 |
| US-20150031715-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | ITGAV, ITGA1, ITGA4 | ITGB1 6/4885ITGA4 3/4885ITGA2 4/4885 |
| US-20060128748-A1 | Bicyclic triazole alpha4 integrin inhibitors | ITGA4, ITGB4, ITGB5 | ITGB1 6/4885ITGA4 1/4885ITGA2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.